factor Xa inhibitors
The role of factor Xa inhibitors in venous thromboembolism treatment
... The oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, show promise as effective alternatives to the stan- dard therapy for VTE treatment. The clinical trial results show noninferiority ...
7
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
... of factor Xa inhibitors remains chal- lenging due a lack of specific ...Recombinant factor VIIa (rFVIIa) has been effective in some small studies using animals and humans, but results are ...
6
Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation
... with factor Xa inhibitors apixaban, rivaroxaban and edoxa- ban, compared in each case to warfarin, yielded a rela- tively clear image on the therapeutic interest of these three drugs in ...
6
A New Mechanism-Driven Bypassing Strategy for Direct Factor Xa Inhibitors Reveals An Unexpected Property of Target Specific Anticoagulants
... Clot formation is a homeostatic mechanism that prevents blood loss following vascular injury. Its dysregulation can lead to the pathological activation of coagulation and thrombosis. Pharmacologic oral anticoagulation by ...
156
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
... of factor Xa and its cofactor factor Va, assembles on a membrane surface where it converts prothrombin (II) to thrombin ...of factor Xa are essential for factor Xa ...
9
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols
... The factor Xa inhibitors should be stopped at least 24 to 36 hours before low-risk procedures and at least 48 hours before high-risk ...anti-factor Xa assays for factor Xa ...
8
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
... Direct factor Xa inhibitors (apixaban and rivaroxaban) and direct thrombin inhibitors (dabigatran) are approved for stroke prevention in atrial fibrillation and prophylaxis and treatment of ...
10
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
... antagonist (VKA) warfarin has traditionally been used for stroke prevention in these individuals, but effective use of this medication is encumbered by its delayed onset, narrow therapeutic window, numerous drug–drug and ...
11
RIVAROXABAN: AN ORAL DIRECT INHIBITOR OF FACTOR X-A
... direct factor Xa inhibitors, rivaroxaban prolongs prothrombin time and activated partial thrombo plastin time; however, the effect of the drug on these tests is short-lived, with prolongation only ...
6
Concept of a point of care test to detect new oral anticoagulants in urine samples
... direct factor Xa inhibitors because of the higher elimination rate into the ...direct factor Xa inhibi- tor test is that concentrated urine may produce a yellow ...
5
Transitions of care in anticoagulated patients
... the factor Xa inhibitors, rivaroxaban and apixaban, have been approved in the US for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; rivaroxaban is ...
14
Education and practice gaps on atrial fibrillation and anticoagulation: a survey of cardiovascular nurses
... and factor Xa inhibitors rivaroxaban and apixaban have held the promise of simplified dosing without the need for frequent blood testing, concerns persist of bleeding risk and the lack of any ...
10
New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness
... direct factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and the thrombin inhibitor dabigatran, were developed to overcome the limitations of the conventional anticoagulant ...
10
Clinical and pharmacological properties of new oral anticoagulants for the prevention of cerebral thromboembolism: Factor Xa and thrombin inhibitors
... thrombin inhibitors (e.g., dabigatran) and direct factor Xa inhibitors ...thrombin/ factor Xa ...and factor Xa inhibitors, which are new and promising oral ...
8
Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo
... (HUVECs), factor Xa not only bound to EPR-1 but also increased intracellular free calcium, phosphoinositide turnover, tissue factor expression, and release of tissue-type plasminogen activator, ...
9
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
... against factor Xa inhibitors in case of major bleeding or need for urgent surgery is a concern to ...a factor Xa inhibitor suggest several hemostatic agents to reverse the effect, but ...
5
Search | Preprints
... A new series of 1,3,4-oxadiazoles derivatives was synthesized, characterized and evaluated for their in vitro and in vivo anti-thrombotic activity. Compounds (3a-3i) exhibited significant clot lysis with respect to ...
39
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
... pump inhibitors, or other H 2 -receptor antagonists are unlikely to affect the pharma- cokinetics of apixaban by means of their influence on pH or inhibition of ...Other inhibitors of hOCT are also not ...
8
Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations
... FXa inhibitors because they inhibit FXa by potentiation of the natural inhibitory action of antithrombin (AT) that is an endogenous plasma protein (Figure ...
8
Patients with Congenital Factor V Deficiency have Decreased Factor Xa Binding Sites on their Platelets
... of Factor X a from Factor V-deficient patients was normal when platelet binding was ...contains Factor V activity, corrected the Factor X a binding deficiency of the platelets from three ...
9